Inventor
WANG YUGUANG
CN31 patents
⚠️ This page may combine multiple inventors who share the name “WANG YUGUANG”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
SCHERING CORP
12 patentsUS6821978B2Nov 23, 2004
Xanthine phosphodiesterase V inhibitors
SCHERING CORP140 citations99
US5977138ANov 2, 1999
Ether muscarinic antagonists
SCHERING CORP99 citations98
US5889006AMar 30, 1999
Muscarinic antagonists
SCHERING CORP123 citations97
US7304078B2Dec 4, 2007
Thrombin receptor antagonists
SCHERING CORP43 citations96
US6043255AMar 28, 2000
Muscarinic antagonists
SCHERING CORP50 citations95
US6969719B2Nov 29, 2005
Polycyclic guanine phosphodiesterase V inhibitors
SCHERING CORP59 citations94
US7713999B2May 11, 2010
Thrombin receptor antagonists
SCHERING CORP8 citations83
US7888369B2Feb 15, 2011
Oxazoloisoquinoline derivatives as thrombin receptor antagonists
SCHERING CORP4 citations63
US7531544B2May 12, 2009
Xanthine phosphodiesterase V inhibitors
SCHERING CORP2 citations63
US7442712B2Oct 28, 2008
Constrained himbacine analogs as thrombin receptor antagonists
SCHERING CORP6 citations60
US7268141B2Sep 11, 2007
Xanthine phosphodiesterase V inhibitors
SCHERING CORP4 citations60
US6831089B2Dec 14, 2004
Muscarinic antagonists
SCHERING CORP1 citations52
GUANGZHOU MAXINOVEL PHARMACEUTICALS CO LTD
9 patentsUS12473300B2Nov 18, 2025
Thienopyrimidine derivative and preparation method therefor
GUANGZHOU MAXINOVEL PHARMACEUTICALS CO LTD0 citations60
US11078192B2Aug 3, 2021
Aromatic acetylene or aromatic ethylene compound, intermediate, preparation method, pharmaceutical composition and use thereof
GUANGZHOU MAXINOVEL PHARMACEUTICALS CO LTD2 citations60
US10494378B2Dec 3, 2019
Fused ring pyrimidine compound, intermediate, and preparation method, composition and use thereof
GUANGZHOU MAXINOVEL PHARMACEUTICALS CO LTD1 citations59
US12428369B2Sep 30, 2025
Crystal form of aromatic vinyl derivatives, and preparation method therefor and use thereof
GUANGZHOU MAXINOVEL PHARMACEUTICALS CO LTD0 citations56
US11352368B2Jun 7, 2022
Salt of fused ring pyrimidine compound, crystal form thereof and preparation method therefor and use thereof
GUANGZHOU MAXINOVEL PHARMACEUTICALS CO LTD0 citations56
US11384048B2Jul 12, 2022
Aromatic vinyl or aromatic ethyl derivative, preparation method therefor, intermediate, pharmaceutical composition, and application
GUANGZHOU MAXINOVEL PHARMACEUTICALS CO LTD0 citations50
US11066413B2Jul 20, 2021
Aminopyrimidine five-membered heterocyclic compound, and intermediate, preparation method, pharmaceutical composition and application thereof
GUANGZHOU MAXINOVEL PHARMACEUTICALS CO LTD0 citations50
US10611770B2Apr 7, 2020
Condensed-ring pyrimidylamino derivative, preparation method therefor, and intermediate, pharmaceutical composition and applications thereof
GUANGZHOU MAXINOVEL PHARMACEUTICALS CO LTD0 citations48
US10259816B2Apr 16, 2019
Condensed-ring pyrimidylamino derivative, preparation method therefor, and intermediate, pharmaceutical composition and applications thereof
GUANGZHOU MAXINOVEL PHARMACEUTICALS CO LTD0 citations48
CYCLERION THERAPEUTICS INC
4 patentsUS12030874B2Jul 9, 2024
Processes and intermediates for the preparation of soluble guanylate cyclase stimulators
CYCLERION THERAPEUTICS INC1 citations70
US11708361B2Jul 25, 2023
Processes and intermediates for the preparation of soluble guanylate cyclase stimulators
CYCLERION THERAPEUTICS INC2 citations70
US11274096B2Mar 15, 2022
Processes and intermediates for the preparation of soluble guanylate cyclase stimulators
CYCLERION THERAPEUTICS INC2 citations70
US12275724B2Apr 15, 2025
Processes and intermediates for the preparation of soluble guanylate cyclase stimulators
CYCLERION THERAPEUTICS INC0 citations59